The immune system as a chronotoxicity target of the anticancer mTOR inhibitor everolimus

References

• Ahowesso C, Piccolo E, Li XM, Dulong S, Hossard V, La Sorda R, Filipski E, Tinari N, Delaunay F, Iacobelli S, et al. 2010. Relations between strain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in mice. Toxicol Lett. 192:395–401.
   PubMed Web of Science ®Google Scholar
• Ando H, Yanagihara H, Sugimoto K, Hayashi Y, Tsuruoka S, Takamura T, Kaneko S, Fujimura A. 2005. Daily rhythms of P-glycoprotein expression in mice. Chronobiol Int. 22:655–65.
   PubMed Web of Science ®Google Scholar
• Booth J, Robeva A, Rosamilia M. 2010. Everolimus/Afinitor (RAD001) investigator’s brochure. 10th edition. Switzerland: Novartis Pharmaceutical Corporation.
   Google Scholar
• Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, Brell JM, Siu LL. 2012. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol. 30:2919–28.
   PubMed Web of Science ®Google Scholar
• Cain SW, Dennison CF, Zeitzer JM, Guzik AM, Khalsa SB, Santhi N, Schoen MW, Czeisler CA, Duffy JF. 2010. Sex differences in phase angle of entrainment and melatonin amplitude in humans. J Biol Rhythms. 25:288–96.
   PubMed Web of Science ®Google Scholar
• Cao R, Anderson FE, Jung YJ, Dziema H, Obrietan K. 2011. Circadian regulation of mammalian target of rapamycin signaling in the mouse suprachiasmatic nucleus. Neuroscience. 181:79–88.
   PubMed Web of Science ®Google Scholar
• Cao R, Obrietan K. 2010. mTOR signaling and entrainment of the mammalian circadian clock. Mol Cell Pharmacol. 2:125–30.
   PubMedGoogle Scholar
• Chen A, Chen L, Al-Qaisi A, Romond E, Awasthi M, Kadamyan-Melkumyan V, Massarweh S. 2015. Everolimus-induced hematologic changes in patients with metastatic breast cancer. Clin Breast Cancer. 15:48–53.
   PubMed Web of Science ®Google Scholar
• Crowe A, Lemaire M. 1998. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: Comparison with rapamycin. Pharm Res. 15:1666–72.
   PubMed Web of Science ®Google Scholar
• Cui YJ, Cheng X, Weaver YM, Klaassen CD. 2009. Tissue distribution, gender-divergent expression, ontogeny, and chemical induction of multidrug resistance transporter genes (Mdr1a, Mdr1b, Mdr2) in mice. Drug Metab Dispos. 37:203–10.
   PubMed Web of Science ®Google Scholar
• Dallmann R, Okyar A, Levi F. 2016. Dosing-time makes the poison: Circadian regulation and pharmacotherapy. Trends Mol Med. 22:430–45.
   PubMed Web of Science ®Google Scholar
• Dibner C, Schibler U, Albrecht U. 2010. The mammalian circadian timing system: Organization and coordination of central and peripheral clocks. Annu Rev Physiol. 72:517–49.
   PubMed Web of Science ®Google Scholar
• Fasolo A, Sessa C. 2008. mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs. 17:1717–34.
   PubMed Web of Science ®Google Scholar
• Filipski E, Berland E, Ozturk N, Guettier C, Van Der Horst GT, Levi F, Okyar A. 2014. Optimization of irinotecan chronotherapy with P-glycoprotein inhibition. Toxicol Appl Pharmacol. 274:471–79.
   PubMed Web of Science ®Google Scholar
• Filipski E, Lemaigre G, Liu XH, Mery-Mignard D, Mahjoubi M, Levi F. 2004. Circadian rhythm of irinotecan tolerability in mice. Chronobiol Int. 21:613–30.
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Dugue PA, Innominato PF, Bjarnason GA, Focan C, Garufi C, Tumolo S, Coudert B, Iacobelli S, Smaaland R, et al. 2012. Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: A meta-analysis. Ann Oncol. 23:3110–16.
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Li XM, Ozturk N, Cuvier C, Machowiak J, Arrondeau J, Chang-Marchand Y, Espié M, Okyar A, Lévi F. 2017. Consistent dosing-time dependent tolerability of everolimus (EV) in a pilot study in women with metastatic breast cancers (MBC) and in a mouse chronopharmacology investigation. Cancer Research. 77:06–06.
   Web of Science ®Google Scholar
• Haus E, Lakatua DJ, Swoyer J, Sackett-Lundeen L. 1983. Chronobiology in hematology and immunology. Am J Anat. 168:467–517.
   PubMedGoogle Scholar
• Hernandez JP, Mota LC, Huang W, Moore DD, Baldwin WS. 2009. Sexually dimorphic regulation and induction of P450s by the constitutive androstane receptor (CAR). Toxicology. 256:53–64.
   PubMed Web of Science ®Google Scholar
• Hirao J, Nishimura M, Arakawa S, Niino N, Mori K, Furukawa T, Sanbuissho A, Manabe S, Nishihara M, Mori Y. 2011. Sex and circadian modulatory effects on rat liver as assessed by transcriptome analyses. J Toxicol Sci. 36:9–22.
   PubMed Web of Science ®Google Scholar
• Hoogeveen RC, Ballantyne CM, Pownall HJ, Opekun AR, Hachey DL, Jaffe JS, Oppermann S, Kahan BD, Morrisett JD. 2001. Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. Transplantation. 72:1244–50.
   PubMed Web of Science ®Google Scholar
• Hrushesky WJ. 1985. Circadian timing of cancer chemotherapy. Science. 228:73–75.
   PubMed Web of Science ®Google Scholar
• Huynh H, Chow KH, Soo KC, Toh HC, Choo SP, Foo KF, Poon D, Ngo VC, Tran E. 2009. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med. 13:1371–80.
   PubMed Web of Science ®Google Scholar
• Jacobsen W, Serkova N, Hausen B, Morris RE, Benet LZ, Christians U. 2001. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc. 33:514–15.
   PubMed Web of Science ®Google Scholar
• Labrecque N, Cermakian N. 2015. Circadian clocks in the immune system. J Biol Rhythms. 30:277–90.
   PubMed Web of Science ®Google Scholar
• Laplante A, Demeule M, Murphy GF, Beliveau R. 2002. Interaction of immunosuppressive agents rapamycin and its analogue SDZ-RAD with endothelial P-gp. Transplant Proc. 34:3393–95.
   PubMed Web of Science ®Google Scholar
• Lebwohl D, Anak O, Sahmoud T, Klimovsky J, Elmroth I, Haas T, Posluszny J, Saletan S, Berg W. 2013. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Ann N Y Acad Sci. 1291:14–32.
   PubMed Web of Science ®Google Scholar
• Leighton JK, Saber H, Lee H. 2009. Afinitor (Everolimus). Pharmacology/Toxicology Review and Evaluation, Center for Drug Evaluation and Research, Food and Drug Administration. NDA no 22-334. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022334s000_PharmR.pdf
   Google Scholar
• Levi F, Focan C, Karaboue A, De La Valette V, Focan-Henrard D, Baron B, Kreutz F, Giacchetti S. 2007. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev. 59:1015–35.
   PubMed Web of Science ®Google Scholar
• Levi F, Okyar A, Dulong S, Innominato PF, Clairambault J. 2010. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol. 50:377–421.
   PubMed Web of Science ®Google Scholar
• Levi F, Tampellini M, Metzger G, Bizi E, Lemaigre G, Hallek M. 1994. Circadian changes in mitoxantrone toxicity in mice: Relationship with plasma pharmacokinetics. Int J Cancer. 59:543–47.
   PubMed Web of Science ®Google Scholar
• Lu YF, Jin T, Xu Y, Zhang D, Wu Q, Zhang YK, Liu J. 2013. Sex differences in the circadian variation of cytochrome p450 genes and corresponding nuclear receptors in mouse liver. Chronobiol Int. 30:1135–43.
   PubMed Web of Science ®Google Scholar
• Luo H, Duguid W, Chen H, Maheu M, Wu J. 1994. The effect of rapamycin on T cell development in mice. Eur J Immunol. 24:692–701.
   PubMed Web of Science ®Google Scholar
• Moes DJ, Guchelaar HJ, De Fijter JW. 2015. Sirolimus and everolimus in kidney transplantation. Drug Discov Today. 20:1243–49.
   PubMed Web of Science ®Google Scholar
• Morrisett JD, Abdel-Fattah G, Hoogeveen R, Mitchell E, Ballantyne CM, Pownall HJ, Opekun AR, Jaffe JS, Oppermann S, Kahan BD. 2002. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res. 43:1170–80.
   PubMed Web of Science ®Google Scholar
• Ohdo S. 2010. Chronotherapeutic strategy: Rhythm monitoring, manipulation and disruption. Adv Drug Deliv Rev. 62:859–75.
   PubMed Web of Science ®Google Scholar
• Ohkura N, Oishi K, Sekine Y, Atsumi G, Ishida N, Matsuda J, Horie S. 2007. Comparative study of circadian variation in numbers of peripheral blood cells among mouse strains: Unique feature of C3H/HeN mice. Biol Pharm Bull. 30:1177–80.
   PubMed Web of Science ®Google Scholar
• Okazaki H, Matsunaga N, Fujioka T, Okazaki F, Akagawa Y, Tsurudome Y, Ono M, Kuwano M, Koyanagi S, Ohdo S. 2014. Circadian regulation of mTOR by the ubiquitin pathway in renal cell carcinoma. Cancer Res. 74:543–51.
   PubMed Web of Science ®Google Scholar
• Ozturk N, Okyar A, Li XM, Lévi F. 2014. The circadian timing system as a toxicity target of the anticancer mTor inhibitor everolimus in mice. Basic Clin Pharmacol Toxicol. 115:318.
   Google Scholar
• Pritchett D, Reddy AB. 2015. Circadian clocks in the hematologic system. J Biol Rhythms. 30:374–88.
   PubMed Web of Science ®Google Scholar
• Renaud HJ, Cui JY, Khan M, Klaassen CD. 2011. Tissue distribution and gender-divergent expression of 78 cytochrome P450 mRNAs in mice. Toxicol Sci. 124:261–77.
   PubMed Web of Science ®Google Scholar
• Sanchez Fructuoso A, Calvo N, Moreno MA, Giorgi M, Barrientos A. 2007. Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients. Transplant Proc. 39:2242–44.
   PubMed Web of Science ®Google Scholar
• Schulz P, Steimer T. 2009. Neurobiology of circadian systems. CNS Drugs. 23(Suppl 2):3–13.
   PubMedGoogle Scholar
• Sletvold O, Smaaland R, Laerum OD. 1991. Cytometry and time-dependent variations in peripheral blood and bone marrow cells: A literature review and relevance to the chronotherapy of cancer. Chronobiol Int. 8:235–50.
   PubMed Web of Science ®Google Scholar
• Sofroniadou S, Goldsmith D. 2011. Mammalian target of rapamycin (mTOR) inhibitors: Potential uses and a review of haematological adverse effects. Drug Saf. 34:97–115.
   PubMed Web of Science ®Google Scholar
• Wang J, Lv C, Xie T, Ouyang J. 2015. The variance of peripheral blood lymphocyte subsets of streptozotocin-induced diabetic mice after bone marrow transplantation. Int J Clin Exp Med. 8:4115–21.
   PubMed Web of Science ®Google Scholar
• Zhang YK, Yeager RL, Klaassen CD. 2009. Circadian expression profiles of drug-processing genes and transcription factors in mouse liver. Drug Metab Dispos. 37:106–15.
   PubMed Web of Science ®Google Scholar